↓ Skip to main content

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis

Overview of attention for article published in Targeted Oncology, October 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age and source (55th percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
9 Mendeley
Title
Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis
Published in
Targeted Oncology, October 2018
DOI 10.1007/s11523-018-0597-7
Pubmed ID
Authors

Ondrej Fiala, Veronika Veskrnova, Renata Chloupkova, Alexandr Poprach, Igor Kiss, Katerina Kopeckova, Ladislav Dusek, Lubomir Slavicek, Milan Kohoutek, Jindrich Finek, Marek Svoboda, Lubos Petruzelka, Ludmila Boubliková, Josef Dvorak, Bohuslav Melichar, Tomas Buchler

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 9 100%

Demographic breakdown

Readers by professional status Count As %
Professor > Associate Professor 3 33%
Lecturer 2 22%
Unspecified 1 11%
Student > Postgraduate 1 11%
Student > Doctoral Student 1 11%
Other 0 0%
Unknown 1 11%
Readers by discipline Count As %
Medicine and Dentistry 5 56%
Unspecified 1 11%
Earth and Planetary Sciences 1 11%
Nursing and Health Professions 1 11%
Unknown 1 11%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2018.
All research outputs
#15,549,350
of 23,109,468 outputs
Outputs from Targeted Oncology
#270
of 556 outputs
Outputs of similar age
#219,492
of 350,381 outputs
Outputs of similar age from Targeted Oncology
#5
of 18 outputs
Altmetric has tracked 23,109,468 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 556 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,381 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.